Emergency Medicine Journal
June 1, 2011
Miguel Galicia, Santiago Nogué, Òscar Miró
To describe the epidemiological profile and clinical manifestations of liquid ecstasy (GHB) poisonings. All cases of GHB poisoning or overdose admitted to the Emergency Department (ED) of the Hospital Clinic (Barcelona) between 2000 and 2007 were recorded. A total of 505 patients (mean age 24.7 years, 68% men) were included. Most patients were brought to the hospital by ambulance (98%), during...
Journal of Psychopharmacology
May 26, 2011
Kim P. C. Kuypers, Marleen Wingen, Armin Heinecke et al.
19 citations
The aim of the present study was to identify the neural substrate underlying memory impairment due to a single dose of MDMA (3,4-methylenedioxymethamphetamine) by means of pharmaco-MRI. Based on previous behavioral results it was hypothesized that this deficit could be attributed to a specific influence of MDMA on encoding. Fourteen Ecstasy users participated in this double-blind,...
British Journal of Pharmacology
May 26, 2011
Ján Kehr, Fumio Ichinose, Shimako Yoshitake et al.
BACKGROUND AND PURPOSE: The designer drug 1-(4-methylphenyl)-2-methylaminopropan-1-one (4-methylmethcathinone, mephedrone) is reported to possess psychostimulant, entactogenic and hallucinogenic effects. The purpose of this study was to examine the effects of acute administration of mephedrone on extracellular levels of dopamine (DA) and 5-HT in the nucleus accumbens of awake rats and compare...
Forensic Science International
May 20, 2011
Jennifer L. Pilgrim, Dimitri Gerostamoulos, Noel Woodford et al.
44 citations
The use of MDMA (ecstasy) in Australia is a widespread and growing problem, promoting acute toxicity and disease which can lead to premature death in users. We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity. Despite the highly reported toxicity of this drug combination, there are...
The Open Forensic Science Journal
May 12, 2011
Steven B. Karch
31 citations
In less than 50 years the number of MDMA (3,4-Methylenedioxymethamphetamine or Ecstasy) users in the United States has gone from zero to nearly three million.For all of its popularity, very little is known about MDMA's probable mechanism of action, or the mechanisms by which it causes death and disability.Even less is known about this drug's checkered past, including dangerous plans by various...
Neuropsychopharmacology
May 11, 2011
Janelle H. P. van Wel, Kim P. C. Kuypers, Eef L. Theunissen et al.
52 citations
3,4-Methylenedioxymethamphetamine (MDMA) or 'ecstasy' has been associated with memory deficits during abstinence and intoxication. The human neuropharmacology of MDMA-induced memory impairment is unknown. This study investigated the role of 5-HT(2A) and 5-HT(1A) receptors in MDMA-induced memory impairment. Ketanserin is a 5-HT(2A) receptor blocker and pindolol a 5-HT(1A) receptor blocker. It...
Journal of Neuroscience
May 11, 2011
Philippe Huot, Tom H. Johnston, Katie D. Lewis et al.
83 citations
l -3,4-Dihydroxyphenylalanine ( l -DOPA) is the most effective treatment for Parkinson's disease, but long-term l -DOPA administration is marred by the emergence of motor complications, namely, dyskinesia and a shortening of antiparkinsonian benefit (wearing-OFF). 3,4-Methylenedioxymethamphetamine (MDMA) is unique in that it exerts antidyskinetic effects and may enhance antiparkinsonian actions...
Brain Research
May 4, 2011
Gender differences in hyperthermia and regional 5-HT and 5-HIAA depletion in the brain following MDMA administration in rats.
Journal of Pharmacy Technology
May 1, 2011
Matthew L. Banks, Jon E. Sprague
Objective: To evaluate the scientific rationale and efficacy of pharmacologic and nonpharmacologic treatments for sympathomimetic-induced hyperthermia and related sequelae. Data Sources: Literature was accessed through MEDLINE (1940-September 2010) using the terms MDMA [3,4-methylenedioxymethamphetamine], methamphetamine, toxicity, and hyperthermia. In addition, reference citations from...
Clinical Pharmacokinetics
May 1, 2011
Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.